Transactions
16
Insider / Ultragenyx Pharmaceutical Inc.
Horn Howard
Chief Financial Officer at Ultragenyx Pharmaceutical Inc.
- Ticker
- RARE
- First filing on record
- October 14, 2025
- Latest trade on record
- October 15, 2026
- SEC filings
- EDGAR ↗
Horn Howard, Chief Financial Officer at Ultragenyx Pharmaceutical Inc., has disclosed 16 transactions in RARE since October 14, 2025: 0 purchases (0 open-market buys) and 13 sales, worth about $1.4M at the reported prices. The latest was filed October 19, 2026, 4 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
13
Avg. disclosure lag
2.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Horn Howard made no purchases and 12 sales worth $1.2M, plus 3 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Horn Howard has traded 1 stock on record; the largest by dollars is RARE.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 12 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 13 | 57,757 | $1.4M |
| A | Grant or award | 3 | 100,769 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 14 | 0 | 11 · $1.1M |
| 2025 | 2 | 0 | 2 · $362K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| RARE | Sell S | October 15, 2026 | October 19, 2026 | 4d | 7,066 | $15 | $108K | Form 4 ↗ | ||
| RARE | Sell S | August 3, 2026 | August 4, 2026 | 1d | 4,696 | $25 | $117K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | July 1, 2026 | July 6, 2026 | 5d | 4,698 | $33 | $156K | late10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | June 1, 2026 | June 1, 2026 | 0d | 4,653 | $24 | $111K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | May 1, 2026 | May 4, 2026 | 3d | 4,683 | $25 | $117K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 59,952 | — | — | derivative | Form 4 ↗ | |
| RARE | Other A | April 16, 2026 | April 20, 2026 | 4d | 34,674 | — | — | Form 4 ↗ | ||
| RARE | Sell S | April 1, 2026 | April 2, 2026 | 1d | 4,683 | $21 | $98K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | March 3, 2026 | March 3, 2026 | 0d | 1,635 | $22 | $37K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 3,119 | $23 | $70K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | March 2, 2026 | March 3, 2026 | 1d | 5,290 | $23 | $121K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Other A | March 1, 2026 | March 3, 2026 | 2d | 6,143 | — | — | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | February 2, 2026 | February 3, 2026 | 1d | 3,061 | $24 | $72K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | January 2, 2026 | January 5, 2026 | 3d | 3,150 | $23 | $72K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | December 10, 2025 | December 11, 2025 | 1d | 3,081 | $36 | $112K | 10b5-1 plan | Form 4 ↗ | |
| RARE | Sell S | October 13, 2025 | October 14, 2025 | 1d | 7,942 | $32 | $250K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 19, 2026 | Form 4 | 0001193125-26-425032 | 1 | published | EDGAR ↗ |
| August 4, 2026 | Form 4 | 0001193125-26-332536 | 1 | published | EDGAR ↗ |
| July 6, 2026 | Form 4 | 0001193125-26-296128 | 1 | published | EDGAR ↗ |
| June 1, 2026 | Form 4 | 0001786335-26-000002 | 1 | published | EDGAR ↗ |
| May 4, 2026 | Form 4 | 0001193125-26-204402 | 1 | published | EDGAR ↗ |
| April 20, 2026 | Form 4 | 0001193125-26-164247 | 2 | published | EDGAR ↗ |
| April 2, 2026 | Form 4 | 0001193125-26-140702 | 1 | published | EDGAR ↗ |
| March 3, 2026 | Form 4 | 0001193125-26-089107 | 4 | published | EDGAR ↗ |
| February 3, 2026 | Form 4 | 0001193125-26-034832 | 1 | published | EDGAR ↗ |
| January 5, 2026 | Form 4 | 0001193125-26-002410 | 1 | published | EDGAR ↗ |
| December 11, 2025 | Form 4 | 0001193125-25-315460 | 1 | published | EDGAR ↗ |
| October 14, 2025 | Form 4 | 0001193125-25-238708 | 1 | published | EDGAR ↗ |
Other insiders at Ultragenyx Pharmaceutical Inc.
- Parschauer Karah Herdman EVP and Chief Legal Officer 8 rows
- Huizenga Theodore Alan SVP, Chief Accounting Officer 7 rows
- Crombez Eric EVP and Chief Medical Officer 5 rows
- Harris Erik EVP & Chief Commercial Officer 4 rows
- Huang Dennis Karl See Remarks 4 rows
- KAKKIS EMIL D President & CEO 4 rows
- Pinion John Richard See Remarks 4 rows
- Dunsire Deborah Director 3 rows
- Sanders Corazon (Corsee) D. Director 3 rows
- SULIMAN SHEHNAAZ Director 3 rows
Everyone on file, with contracts and lobbying under the company's name: Ultragenyx Pharmaceutical Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 12 | 16 | October 14, 2025 | October 19, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.